Pacific Biosciences of California Inc (NASDAQ:PACB) has a beta value of 2.00 and has seen 7.96 million shares traded in the last trading session. The company, currently valued at $400.25M, closed the last trade at $1.47 per share which meant it gained $0.09 on the day or 6.52% during that session. The PACB stock price is -889.8% off its 52-week high price of $14.55 and 14.97% above the 52-week low of $1.25. The 3-month trading volume is 9.79 million shares.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Sporting 6.52% in the green in last session, the stock has traded in the red over the last five days, when the PACB stock price touched $1.47 or saw a rise of 10.91%. Year-to-date, Pacific Biosciences of California Inc shares have moved -85.02%, while the 5-day performance has seen it change -5.16%. Over the past 30 days, the shares of Pacific Biosciences of California Inc (NASDAQ:PACB) have changed -60.48%.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
Figures show that Pacific Biosciences of California Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -78.12% over the past 6 months, with this year growth rate of 9.91%, compared to 14.60% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 25.00% and 10.70% for the next quarter. Revenue growth from the last financial year stood is estimated to be 2.10%.
11 analysts offering their estimates for the company have set an average revenue estimate of $42.96 million for the current quarter. 10 have an estimated revenue figure of $46.63 million for the next quarter concluding in Jun 2024.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.76% over the past 5 years. Earnings growth for 2024 is a modest 15.58% while over the next 5 years, the company’s earnings are expected to decrease by -1.00%.
PACB Dividends
Pacific Biosciences of California Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
